Cosciens Biopharma (CSCI) said Thursday it has started the phase 2a clinical efficacy study of its avenanthramides product, which it is developing for potential applications in managing conditions related to inflammation.
In phase 2a of the study, 20 patients with mild to moderate inflammation will participate. This phase is designed to assess potential efficacy in two arms with patients receiving selected doses of 480 mg and 960 mg per day, the company said. Initial dosing is expected to occur on March 14.
The Data Safety and Monitoring Board recommended initiating phase 2a after phase 1, done in November 2023, showed the favorable safety profile of the product, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。